Original Articles
14 April 2025
Early Access
Correlation between neutrophils-to-lymphocyte ratio and soluble FMS-like tyrosine kinase 1 in pregnant women with preeclampsia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
220
Views
53
Downloads
Authors
Preeclampsia (PE) is a multi-system syndrome in pregnancy that affects 5-10% of pregnancies and is a significant cause of perinatal morbidity and mortality. Therefore, an early and precise diagnosis of PE is needed. Several biomarkers have been used for this diagnosis. The neutrophil-to-lymphocyte ratio (NLR) is a potential biomarker that can be assessed through routine blood tests, but few studies have been conducted to compare NLR with other conventional markers. This study analyzes the correlation between NLR and soluble FMS-like tyrosine kinase 1 (sFLT-1) levels in pregnant women with PE. This study used a cross-sectional study among 88 patients divided into two groups (normal n=44, PE n=44) by consecutive sampling. All research subjects took venous blood samples and performed routine blood tests and sFLT-1. All statistical analyses were performed using the Statistical Program for Social Sciences (IBM SPSS 24, Chicago, IL, USA). There was no significant difference between the NLR in the control and PE groups, which were 5.45 (0.5) and 5.87 (5.5), respectively. The sFLT-1 marker increased significantly and increased in normal pregnancy and PE, namely 6336 (579) pg/mL and 18,775 (9841) pg/mL. NLR and log sFLT-1 were not correlated in PE (rho=0.11, p=0.451), but they were related in normal pregnancy (rho=0.705, p<0.001). In conclusion, there is a difference in sFLT-1 levels in PE and controls but no difference in the NLR biomarker. NLR does not correlate with the sFLT-1 biomarker.
Altmetrics
Downloads
Download data is not yet available.
Citations
Ali M, Ahmed M, Memon M, et al. Preeclampsia: a comprehensive review. Clin Chim Acta 2024;563:119922. DOI: https://doi.org/10.1016/j.cca.2024.119922
Fox R, Kitt J, Leeson P, et al. Preeclampsia: risk factors, diagnosis, management, and the cardiovascular impact on the offspring. J Clin Med 2019;8:1625. DOI: https://doi.org/10.3390/jcm8101625
Kahramanoglu Ö, Schiattarella A, Demirci O, et al. Preeclampsia: state of art and future perspectives. A special focus on possible preventions. J Obstet Gynaecol 2022;42:766-77. DOI: https://doi.org/10.1080/01443615.2022.2048810
Boutin A, Guerby P, Gasse C, et al. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study. Am J Obstet Gynecol 2021;224:204.e1-e7. DOI: https://doi.org/10.1016/j.ajog.2020.08.008
Kang Q, Li W, Yu N, et al. Predictive role of neutrophil-to-lymphocyte ratio in preeclampsia: a meta-analysis including 3982 patients. Pregnancy Hypertens 2020;20:111-8. DOI: https://doi.org/10.1016/j.preghy.2020.03.009
Nguyen TH, Bui T, Vo T, et al. Predictive value of the sFlt-1 and PlGF in women at risk for preeclampsia in the south of Vietnam. Pregnancy Hypertens 2018;14:37-42. DOI: https://doi.org/10.1016/j.preghy.2018.07.008
Mannaerts D, Heyvaert S, De Cordt C, et al. Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? J Matern Fetal Neonatal Med 2019;32:1412-9. DOI: https://doi.org/10.1080/14767058.2017.1410701
Acharya N, Mohammad S, Mohammad S, et al. Neutrophil-lymphocyte ratio as a bio- inflammatory prognostic marker of fetomaternal outcomes of preeclampsia: a narrative review. J Pharm Res Int 2021;33:1-8. DOI: https://doi.org/10.9734/jpri/2021/v33i62A35142
Cheng SB, Nakashima A, Huber WJ, et al. Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors. Cell Death Dis 2019;10:927. DOI: https://doi.org/10.1038/s41419-019-2162-4
Zhao X, Zhang X, Wu Z, et al. Up-regulation of microRNA-135 or silencing of PCSK6 attenuates inflammatory response in preeclampsia by restricting NLRP3 inflammasome. Mol Med 2021;27:82. DOI: https://doi.org/10.1186/s10020-021-00335-x
Wang J, Zhu QW, Cheng XY, et al. Assessment efficacy of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in preeclampsia. J Reprod Immunol 2019;132:29-34. DOI: https://doi.org/10.1016/j.jri.2019.02.001
Chiang YT, Seow KM, Chen KH. The pathophysiological, genetic, and hormonal changes in preeclampsia: a systematic review of the molecular mechanisms. Int J Mol Sci 2024;25:4532. DOI: https://doi.org/10.3390/ijms25084532
Ye D, Li S, Ma Z, et al. Diagnostic value of platelet to lymphocyte ratio in preeclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 2023;36:2234540. DOI: https://doi.org/10.1080/14767058.2023.2234540
Biswas M, Belle VS, Maripini N, Prabhu K. Neutrophil-lymphocyte ratio in pregnancy-associated maternal complications: a review. Asian Pac J Reprod 2021;10:252-61. DOI: https://doi.org/10.4103/2305-0500.331262
Mohamed RA, Ali IA. Role of neutrophil / lymphocyte ratio, uric acid / albumin ratio and uric acid / creatinine ratio as predictors to severity of preeclampsia. BMC Pregnancy Childbirth 2023;23:763. DOI: https://doi.org/10.1186/s12884-023-06083-6
Dröge LA, Perschel FH, Stütz N, et al. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study. Hypertension 2021;77:461-71. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.120.15146
Gaccioli F, Sovio U, Gong S, et al. Increased placental sFLT1 (soluble fms-like tyrosine kinase receptor-1) drives the antiangiogenic profile of maternal serum preceding preeclampsia but not fetal growth restriction. Hypertension 2022;80:325-34. DOI: https://doi.org/10.1161/HYPERTENSIONAHA.122.19482
Biwer LA, Man JJ, Ulzurrun JFI, et al. Prior Sflt1 induced preeclampsia exacerbates post-partum hypertension-mediated aortic stiffness and hypercholesterolemia-induced atherosclerotic inflammation. Hypertension 2023;80:A023. DOI: https://doi.org/10.1161/hyp.80.suppl_1.023
Tasta O, Parant O, Hamdi S, et al. Evaluation of the prognostic value of the sFlt-1/PlGF ratio in early-onset preeclampsia. Am J Perinatol 2020;38:292-8. DOI: https://doi.org/10.1055/s-0040-1709696
Miller JJ, Higgins V, Melamed N, et al. Clinical validation of the sFlt-1:PlGF ratio as a biomarker for preeclampsia diagnosis in a high-risk obstetrics unit. J Appl Lab Med 2023;8:457-68. DOI: https://doi.org/10.1093/jalm/jfad003
Ohkuchi A, Saito S, Yamamoto T, et al. Short-term prediction of preeclampsia using the sFlt-1/PlGF ratio: a subanalysis of pregnant Japanese women from the PROGNOSIS Asia study. Hypertens Res 2021;44:813-21. DOI: https://doi.org/10.1038/s41440-021-00629-x
Nikuei P, Rajaei M, Roozbeh N, et al. Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsia. BMC Pregnancy Childbirth 2020;20:80. DOI: https://doi.org/10.1186/s12884-020-2744-2
Park Y, Kim Y, Kim HY, et al. Serum sFlt-1, cystatin C and cathepsin B are potential severity markers in preeclampsia: a pilot study. Arch Gynecol Obstet 2020;301:955-62. DOI: https://doi.org/10.1007/s00404-020-05478-6
Aminuddin NA, Sutan R, Mahdy Z, et al. The feasibility of soluble Fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF) ratio biomarker in predicting preeclampsia and adverse pregnancy outcomes among medium to high risk mothers in Kuala Lumpur, Malaysia. PLoS One 2022;17:e0265080. DOI: https://doi.org/10.1371/journal.pone.0265080
Walentowicz-Sadlecka M, Domaracki P, Sadlecki P, et al. Assessment of the SFlt-1 and sFlt-1/25(OH)D ratio as a diagnostic tool in gestational hypertension (GH), preeclampsia (PE), and gestational diabetes mellitus (GDM). Dis Markers 2019;2019:5870239. DOI: https://doi.org/10.1155/2019/5870239
Mayer-Pickel K, Kolovetsiou-Kreiner V, Stern C, et al. Effect of low-dose aspirin on soluble FMS-like tyrosine kinase 1/placental growth factor (sFlt-1/PlGF ratio) in pregnancies at high risk for the development of preeclampsia. J Clin Med 2019;8:1429. DOI: https://doi.org/10.3390/jcm8091429
Lou W, Jiang F, Hu J, et al. Maternal serum angiogenic factor sFlt-1 to PlGF ratio in preeclampsia: a useful marker for differential diagnosis and prognosis evaluation in chinese women. Dis Markers 2019;2019:6270187. DOI: https://doi.org/10.1155/2019/6270187
Raio L, Bersinger N, Malek A, et al. Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia: a pilot study. J Hypertens 2019;37:1012-7. DOI: https://doi.org/10.1097/HJH.0000000000002003
Pant V, Yadav B, Sharma J. A cross sectional study to assess the sFlt-1:PlGF ratio in pregnant women with and without preeclampsia. BMC Pregnancy Childbirth 2019;19:266. DOI: https://doi.org/10.1186/s12884-019-2399-z
Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta. Biomolecules 2020;10:953. DOI: https://doi.org/10.3390/biom10060953
Simón E, Herraiz I, Villalaín C, et al. Correlation of Kryptor and Elecsys® immunoassay sFlt-1/PlGF ratio on early diagnosis of preeclampsia and fetal growth restriction: a case-control study. Pregnancy Hypertens 2020;20:44-9. DOI: https://doi.org/10.1016/j.preghy.2020.03.002
How to Cite
Correlation between neutrophils-to-lymphocyte ratio and soluble FMS-like tyrosine kinase 1 in pregnant women with preeclampsia. (2025). Italian Journal of Medicine. https://doi.org/10.4081/itjm.2025.1924
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.